Showing results (151-160 of 165) with videos related to
Sort By:
Pageof 17
Blood|November 1, 1988
Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alphaS L Giardina, H A Young, C R Faltynek, et al.British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II studyA Martin, S Nerenstone, W J Urba, et al.Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.Cancer Research|April 1, 1989
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanomaR L Miller, R G Steis, J W Clark, et al.Cancer|January 5, 2000
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumorsD P Ryan, T J Lynch, M L Grossbard, et al.Journal of the National Cancer Institute|April 18, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trialR G Steis, L A VanderMolen, D L Longo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavityR G Steis, W J Urba, L A VanderMolen, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.Pageof 17